September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
Finasteride and dutasteride are not recommended for feminizing therapy due to limited effectiveness and potential risks.
1 citations
,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
6 citations
,
July 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride and dutasteride have limited use in feminising therapy and are not recommended for routine use.
9 citations
,
August 2019 in “Clinical genitourinary cancer” Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.